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Abstract  
 Learning to associate cues or contexts with potential threats or rewards is adaptive 
and enhances survival. Both aversive and appetitive memories are therefore powerful drivers 
of behaviour but the inappropriate expression of conditioned responding to fear- and drug-
related stimuli can develop into anxiety-related and substance abuse disorders, respectively. 
These disorders are associated with abnormally persistent emotional memories and 
inadequate treatment, often leading to symptom relapse. Studies show that cannabidiol, the 
main non-psychotomimetic phytocannabinoid found in Cannabis sativa, reduces anxiety via 
serotonin1A and (indirect) cannabinoid receptor activation in paradigms assessing innate 
responses to threat. Accumulating evidence from animal studies investigating the effects of 
cannabidiol on fear memory processing also indicates that it reduces learned fear in 
paradigms that are translationally relevant to phobias and post-traumatic stress disorder. 
Cannabidiol does so by reducing fear expression acutely, and by disrupting fear memory 
reconsolidation and enhancing fear extinction, both of which can result in the lasting 
reduction of learned fear. Recent studies have also begun to determine the effects of 
cannabidiol on drug memory expression using paradigms with translational relevance to 
addiction. Emerging evidence suggests that cannabidiol reduces the expression of drug 
memories acutely and by disrupting their reconsolidation. Here we review the literature 
demonstrating the anxiolytic effects of cannabidiol before focusing on studies investigating 
its effects on various fear and drug memory processes. Understanding how cannabidiol 
regulates emotion and emotional memory processing may eventually lead to its use in 
treating anxiety-related and substance abuse disorders.  
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Introduction 
 Anxiety (e.g. generalized and social anxiety, panic, phobias), trauma-related (i.e. post-
traumatic stress disorder (PTSD)), and substance abuse disorders are serious forms of mental 
illness associated with a significant lifetime prevalence. These disorders pose an enormous 
social and financial burden as they are often chronic in nature and inadequately treated (Di 
Luca et al., 2011). Certain anxiety-related disorders (i.e. phobias, PTSD) and addiction are 
characterized by aberrant and persistent emotional memories of fear- and drug-related 
stimuli. These discrete or contextual cues can trigger the emergence of symptoms or even 
their re-emergence after treatment, highlighting the limited effectiveness of currently 
available psychological and pharmacological therapies to curtail symptom relapse over the 
long-term (Tronson and Taylor, 2013; Everitt, 2014; Kindt, 2014; Singewald et al., 2015). 
Moreover, there is also significant co-morbidity between substance abuse disorders and 
PTSD, which can further complicate how PTSD develops and is treated. For example, the 
learning and memory processes involved in the psychological therapies that are used for 
treating PTSD can be adversely affected by different abused drugs, which may also have 
complex drug-drug interactions with pharmacological treatments for PTSD (Tipps et al., 
2014). Thus there is an urgent need to improve the treatment of these disorders.  
 An area of real promise in this field concerns the use of existing or novel medications 
as adjuncts to psychological therapies to enhance the efficacy of treatment. Cannabidiol 
(CBD) is one such drug that shows therapeutic potential in a broad range of neurological and 
psychiatric diseases (Campos et al., 2012b). This phytocannabinoid is the main non-
psychotomimetic constituent of the Cannabis sativa plant and mounting evidence indicates 
that CBD has anxiolytic properties (Blessing et al., 2015). Emerging preclinical and clinical 
evidence also indicates that CBD regulates different aversive and appetitive memory 
processes (Prud‟homme et al., 2015; Jurkus et al., 2016), in keeping with the findings of 
recent studies showing a role for CBD in modulating other types of memory, such as novel 
object and social recognition, in cognitively impaired animals (Fagherazzi et al., 2012; Cheng 
et al., 2014). In this paper we begin with a brief historical account of the discovery of CBD 
and touch on the first studies that investigated its behavioural effects in rodents and humans. 
We then review the literature on CBD regulation of anxiety and the pharmacological and 
brain mechanisms involved. The bulk of the paper focuses on discussing the findings from 
the growing number of mostly preclinical studies that have examined the regulation of 
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learned fear and, more recently, addictive drug memory processing by CBD. Importantly, 
these studies have used experimental procedures with clinical relevance for understanding the 
psychological and neurobiological mechanisms involved in the pathophysiology and 
treatment of anxiety-related and substance abuse disorders. 
 
CBD discovery and initial studies on its behavioural effects 
The Cannabis sativa plant contains more than 100 chemically related terpenephenol 
components called phytocannabinoids (Izzo et al., 2009; Gold, 2015). Since the seminal work 
of Raphael Mechoulam‟s group in the 1960s, Delta-9-tetrahydrocannabinol (THC) is 
considered the main component responsible for the pharmacological effects of the plant 
(Gaoni and Mechoulam, 1964). The second major component of most samples of Cannabis 
sativa is CBD. Originally isolated by Adams and co-workers in 1940 (Adams et al., 1940), its 
structure was elucidated by Mechoulam and Shvo in 1963. Although the CBD molecule is 
similar to THC, it has a distinct spatial conformation that could help to explain their different 
pharmacological properties. Whereas THC has a planar conformation, CBD presents a “bent” 
structure with two rings at a right angle to each other (Burstein, 2015). 
 Initial studies performed in the 1970s, mostly in Brazil, indicated that CBD could 
block some effects induced by THC in rodents (Karniol and Carlini, 1973; Russo and Guy, 
2006). Following these initial studies, Zuardi and collaborators investigated if CBD could 
prevent the effects of high doses of THC in healthy human volunteers. They found that it 
attenuates the psychotomimetic and anxiogenic effects of THC (Zuardi et al., 1982). 
Although the mechanisms of action of these two drugs were completely unknown at that 
time, the fact that not all effects of THC were blocked by CBD indicated that the latter was 
not simply an antagonist of a putative THC receptor. On the contrary, the study suggested 
that CBD possesses its own antipsychotic and anxiolytic properties (Zuardi et al., 1982).  
 
Laboratory animal tests used to assess the anxiolytic properties of CBD 
The potential anxiolytic effect of CBD was initially investigated in preclinical studies. 
Several animal tests have been employed to explore the effects of putative anxiolytic drugs 
and the neurobiology of anxiety, which can be defined separately to fear as the emotional 
response to potential or anticipated (as opposed to actual and present) threat (Tovote et al., 
2015). These tests are based on the measurement of defensive behaviours (either active or 
inhibitory) expressed in response to a threatening or unpleasant stimulus (Campos et al., 
2013a). The initial preclinical studies investigating the possible anxiolytic-like effects of 
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CBD were performed in learning-based models and produced mixed results. These apparently 
conflicting results were later explained by Guimaraes et al. (1990) using the elevated plus-
maze (EPM). This is a commonly used test to investigate anxiety-like behaviour in preclinical 
studies and is based on the natural aversion that rodents show to open spaces (Handley and 
Mithani, 1984; Pellow et al., 1985; Treit et al., 1993; Carobrez and Bertoglio, 2005).  
Using the EPM, and performing a full dose-response curve in rats, Guimaraes and co-
workers showed that acute systemic administration of CBD produces a typical „bell-shaped‟ 
dose-response curve, being anxiolytic at low and intermediate doses but not at high doses. 
Although some contradictory results exist in the literature, most studies using unlearned or 
operant conditioning models of anxiety have confirmed these initial findings and the studies 
investigating CBD effects in classical (Pavlovian) conditioning models also go in the same 
direction, which will be discussed separately below (summarized in Tables 1-2). Moreover, 
these anxiolytic effects of CBD in animals have been replicated in human studies using 
healthy subjects exposed to anxiety-provoking stimuli or situations (Zuardi et al., 1982, 1993; 
Crippa et al., 2004; Fusar-Poli et al., 2009, 2010) and in patients with anxiety, and possibly 
also substance abuse, disorders (Bergamaschi et al., 2011, Crippa et al., 2011; Hurd et al., 
2015; Shannon and Opila-Lehman, 2016; summarized in Table 3). 
 
Pharmacological mechanisms and brain sites involved in the anxiolytic effects of CBD 
The potential therapeutic effects of CBD have been related to multiple 
pharmacological mechanisms, including the agonism of serotonin 5-HT1A receptors, 
inhibition of re-uptake and/or metabolism of the endocannabinoid anandamide (resulting 
indirectly in cannabinoid receptor activation),  activation of transient receptor potential 
vanilloid 1 (TRPV1) channels, inhibition of adenosine re-uptake, antagonism of GPR55, 
agonism of PPARγ receptors, intracellular Ca2+ increase, and anti-oxidative effects, among 
others (summarized in Fig 1; the pharmacological nomenclature used throughout conforms 
with The Concise Guide to PHARMACOLOGY (Alexander et al., 2013)). These 
pharmacological mechanisms have been discussed recently in several reviews (Izzo et al., 
2009; Campos et al., 2012a; Ibeas Bih,et al., 2015; McPartland et al., 2015), to which the 
reader is referred. So far, however, only two of these mechanisms - 5-HT1A receptor 
activation and indirect potentiation of endocannabinoid transmission - have been implicated 
in the attenuation of defensive responses to threatening or stressful stimuli. 
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Two primary brain systems organize defensive responses to threatening stimuli: one 
responsive to innate threats and the other responsible for the association between neutral and 
aversive stimuli, although the neural circuit mechanisms underlying the regulation of anxiety 
and learned fear show considerable overlap (for reviews see McNaughton and Corr, 2004; 
Canteras et al., 2010; Gross & Canteras, 2012; Tovote et al., 2015). The brain areas 
implicated in the anxiolytic effects of cannabidiol include certain medial prefrontal cortical 
subregions (e.g. prelimbic (PL) and infralimbic (IL) cortex), the bed nucleus of the stria 
terminalis (BNST), periaqueductal grey (PAG), and amygdala. This evidence comes from 
preclinical studies and functional imaging studies in humans, which have confirmed the 
involvement of some of these brain areas. For example, CBD reduced amygdala activation in 
both mice and humans (Todd and Arnold, 2016; Crippa et al., 2004). Activity in and 
functional connectivity between the amygdala and anterior cingulate cortex, the homologous 
region to the rodent dorsomedial prefrontal cortex, were both also decreased by CBD when 
viewing fearful facial expressions (Fusar-Poli et al., 2009, 2010).  
 In an initial preclinical study using the EPM test, Campos and Guimarães (2008) 
showed that the anxiolytic-like effects of CBD injected into the dorsolateral PAG (dlPAG) 
were prevented by local treatment with the 5-HT1A receptor antagonist WAY100635. Even if 
this drug can also activate D4 receptors (Chemel et al., 2006), the anti-aversive effects of 
CBD were similar to other 5-HT1A receptor agonists infused into the dlPAG (Graeff, 2002). 
5-HT1A receptor involvement in the acute anxiolytic/anti-stress effect of CBD was further 
demonstrated in other relevant brain regions, including the BNST (Gomes et al., 2011) and IL 
cortex (Marinho et al., 2015). Moreover, systemic treatment with 5-HT1A receptor antagonists 
was also able to prevent this CBD-induced anxiolysis (see Table 1).  
In the marble-burying test and after repeated administration, however, CBD effects on 
anxiety seem to depend on cannabinoid type 1 (CB1) receptors rather than 5-HT1A receptors 
(Casarotto et al., 2010; Campos et al., 2013; Nardo et al., 2014). Even if the (+)-CBD 
enantiomer shows affinity for CB1 receptors, the naturally occurring (-)-CBD does not bind to 
these receptors (Hanus et al., 2005), indicating that the CB1 receptor-mediated anti-aversive 
effects of CBD are probably indirect. Bisogno et al. (2001) showed that CBD blocked the 
reuptake and metabolism of anandamide in vitro. In the same direction, using embryonic 
hippocampal cells, Campos et al. (2013b) showed that the increase in cell proliferation 
induced by CBD is prevented by antagonism of either CB1 or cannabinoid type 2 (CB2) 
receptors, as well as by overexpression of fatty acid amide hydrolase (FAAH), the enzyme 
responsible for anandamide metabolism.  More recently, Dale Deutsch‟s group demonstrated 
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that CBD binds to fatty acid binding proteins necessary for the transport of anandamide from 
the plasma membrane to intracellular FAAH, which might be a primary mechanism by which 
CBD decreases anandamide uptake/metabolism (Elmes et al., 2015). Consistent with these in 
vitro studies, the anti-stress (in mice) and antipsychotic (in humans) effects of repeated CBD 
administration were associated with increased hippocampal and serum levels, respectively, of 
anandamide (Campos et al., 2013b, Leweke et al., 2012). 
 
Emotional learning and memory processing 
We first summarize the psychological mechanisms involved in classical conditioning, 
a type of associative learning whereby discrete cues or contexts come to predict the 
occurrence of threatening or rewarding stimuli, before reviewing the evidence demonstrating 
a role for CBD in regulating different fear and drug memory processes. During conditioning 
an innocuous conditioned stimulus (CS), which can be a discrete cue (e.g. sound, light, odor) 
or a context (e.g. testing chamber/arena), becomes associated with an aversive (e.g. 
footshock) or appetitive (e.g. drug reward availability) unconditioned stimulus (US). After 
conditioning, the CS-US association undergoes consolidation into long-term memory and 
later presentation of or re-exposure to the CS alone initially elicits conditioned fear (e.g. 
freezing, avoidance) or drug-seeking (e.g. lever pressing, place preference) responses (Peters 
et al., 2009). Retrieval of the CS can make emotional memories labile by destabilizing the 
memory trace, which allows for these memories to be maintained or updated through the 
process of reconsolidation (Lee, 2009). Repeated presentations of or prolonged exposure to 
the CS causes the extinction of emotional memories, resulting in the formation of a new CS-
no US association which competes with the original emotional memory to suppress 
conditioned responding to the CS (Peters et al., 2009). Understanding how behavioural and/or 
pharmacological interventions can attenuate conditioned responding, disrupt memory 
reconsolidation, and/or enhance extinction has clinical relevance given that all of these 
mechanisms are potential therapeutic strategies for alleviating the symptoms of PTSD (i.e. 
pathological fear) and addiction (i.e. drug craving) (Tronson and Taylor, 2013; Everitt, 2014; 
Kindt, 2014; Singewald et al., 2015). 
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CBD effects on fear memory processing 
As alluded to above, growing evidence indicates that CBD also regulates learned fear 
(see Table 2). Systemic CBD administration has been shown to reduce the expression of fear 
memory when given acutely (Zuardi and Karniol, 1983; Resstel et al., 2006; Lemos et al., 
2010; Jurkus et al., 2016). CBD has also been reported to impair the acquisition of fear 
learning, given that acute systemic administration before fear conditioning resulted in 
attenuated fear expression during later memory retrieval testing (Levin et al., 2012). Fear 
memory consolidation is equally impaired by acute systemic administration of CBD when 
given after conditioning (Stern et al., 2016). In contrast, the reported effects of repeated CBD 
administration on fear memory expression are still scarce and conflicting. In one study, daily 
injections for 14 days prior to conditioning enhanced fear expression during retrieval testing, 
suggesting that chronic CBD facilitated fear learning (ElBatsh et al., 2012), whereas another 
study showed no effect of CBD on fear conditioning when administered for 21 days (Cheng 
et al., 2014).  
Studies indicate that CBD also modulates the extinction and reconsolidation of 
conditioned fear, leading to lasting effects on learned fear expression. Intracerebroventricular 
infusions of CBD given before three extinction sessions resulted in enhanced contextual fear 
extinction (Bitencourt et al., 2008). Systemic administration of CBD given acutely before 
extinction has been shown to affect contextual fear extinction depending on the strength of 
fear conditioning beforehand. CBD impaired extinction after weak conditioning but enhanced 
extinction after strong conditioning (Song et al., 2016). However, CBD given systemically 
before auditory fear extinction reduced fear expression acutely without affecting extinction 
memory (Jurkus et al., 2016). Interestingly, a study in humans also showed that CBD had no 
effect on the extinction of visual fear memory when given before extinction but it did 
enhance extinction memory when given immediately after extinction (Das et al., 2013).  
Contrary to the reported facilitatory effects of CBD on fear extinction, this drug has 
been shown to disrupt the reconsolidation of contextual fear memory after its brief retrieval 
(Stern et al., 2012; Gazarini et al., 2015; Stern et al., 2015), although these contrasting effects 
of CBD on fear extinction and memory reconsolidation both result in the lasting reduction of 
learned fear expression. The disruptive effect of systemic CBD administration on 
reconsolidation required that it was given immediately after memory retrieval as CBD had no 
effect if it was given without, or six hours after, retrieval. CBD was also able to disrupt the 
reconsolidation of both newer and older fear memories. Moreover, the subsequent reduction 
of learned fear expression lasted for over 21 days and was not reinstated by later shock 
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presentation, indicating that the effects of CBD were due to disrupted memory 
reconsolidation and not enhanced extinction (Stern et al., 2012).  
In another study, CBD given immediately after retrieval disrupted the reconsolidation 
of an abnormally persistent fear memory when the partial NMDA receptor agonist D-
cycloserine was first administered before retrieval to facilitate memory destabilization. Fear 
memory was strengthened pharmacologically by enhancing adrenergic transmission 
immediately after conditioning, resulting in generalized fear expression and impaired fear 
suppression by extinction (Gazarini et al., 2015). Understanding the mechanisms underlying 
reconsolidation disruption of such fear memories is important because evidence indicates that 
strong fear memories can show resistance to pharmacological disruption of reconsolidation 
(Lee, 2009), which has implications for using this potential therapeutic approach to weaken 
traumatic memories in the treatment of PTSD.  
 
Pharmacological mechanisms and brain sites involved in the effects of CBD on learned 
fear 
 Just as the anxiolytic effects of CBD involve a direct effect on 5-HT1A receptors and 
an indirect effect on cannabinoid receptors via elevated endocannabinoid levels, so too do its 
effects on different fear memory processes. Similarly, there is overlap in the neural circuitry 
involved in mediating the effects of CBD on anxiety and learned fear. The reduction in 
conditioned fear expression induced by CBD was accompanied by attenuated c-Fos 
expression in the PL and IL cortices and the BSNT. Moreover, CBD infusion into the BNST 
or PL cortex reduced fear memory expression, although infusing CBD into the IL cortex 
enhanced the expression of learned fear (Lemos et al., 2010). This discrepancy between the 
effects of CBD infused into the PL or IL cortex is likely due to these medial prefrontal 
cortical subregions exerting opposing influences on learned fear, with the former facilitating 
its expression and the latter being involved in its suppression and/or extinction (Fenton et al., 
2014; Giustino and Maren, 2015). The regulation of conditioned fear expression by CBD in 
these brain areas was shown to be 5-HT1A receptor-dependent (Gomes et al., 2012; Fogaça et 
al., 2014; Marinho et al., 2015). The inhibitory effect of CBD on the acquisition of fear 
conditioning has also been shown to depend on 5-HT1A receptor activation in the nucleus 
accumbens shell (Norris et al., 2016).  
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In contrast to the acquisition and expression of fear memory, the consolidation, 
reconsolidation, and extinction of learned fear involves (indirect) cannabinoid receptor 
activation. The inhibitory effect of CBD on fear memory consolidation was blocked by CB1 
or CB2 receptor antagonist pretreatment (Stern et al., 2016). The facilitatory effect of 
intracerebroventricular CBD infusion on fear extinction was inhibited by prior CB1 receptor 
antagonism but not TRPV1 channel blockade (Bitencourt et al., 2008). CBD was shown to 
act in the IL cortex to facilitate fear extinction as infusing CBD into this region enhanced 
extinction, an effect which also depended on CB1 receptors (Do Monte et al., 2013). The 
disruptive effect of CBD on fear memory reconsolidation was blocked by pretreatment with a 
CB1 receptor antagonist given systemically or infused into the PL cortex, whereas prior 5-
HT1A receptor antagonism had no effect on the disruption of reconsolidation by CBD (Stern 
et al., 2012, 2014).   
 
CBD effects on addictive drug memory processing 
In contrast to the study of fear memories, to date there has been a much more limited 
exploration of the effects of CBD on addictive drug-related memories. This necessitates a 
narrative review of the relevant literature, which follows below. Moreover, the small number 
of studies has been conducted across a variety of experimental paradigms and with different 
drugs of abuse. These drugs can elicit sensitized responses with intermittent repeated 
administration, which is context-dependent and thereby reliant upon context-drug 
associations. Similarly, the acquisition and expression of conditioned place preference 
behaviour depends upon the integrity of context-drug and/or cue-drug associations. Finally, 
cue-drug associations can precipitate cue-induced relapse of drug seeking in rodents 
previously trained to self-administer drug (Aguilar et al., 2009; Steketee and Kalivas, 2011). 
Each of these paradigms can be studied using stimulants (e.g. cocaine, amphetamine), opiates 
(e.g. heroin, morphine), and other drugs (e.g. alcohol, nicotine, etc.). 
Unlike THC, studies have shown that CBD lacks any rewarding effects of its own 
given that it fails to induce conditioned place preference or enhance the reinforcing effects of 
electrical brain self-stimulation (Parker et al., 2004; Vann et al., 2008; Katisdoni et al., 2013). 
In a study of amphetamine-induced locomotor sensitization, infusions of CBD (100 ng) into 
the shell subregion of the nucleus accumbens attenuated the development of locomotor 
sensitization (Renard et al., 2016). While this might suggest that CBD impaired the formation 
of an amphetamine memory that supports locomotor sensitization, these findings were within 
the context of mesolimbic mechanisms involved in the potential antipsychotic action of CBD. 
 This article is protected by copyright. All rights reserved. 
Moreover, even though the attenuation of locomotor sensitization was paralleled by 
modulation of cellular mechanisms of synaptic plasticity, it remains a challenge to 
disambiguate learning-related behavioural effects from modulation of drug reward (c.f. 
Katsidoni et al., 2013; Prud'homme et al., 2015), which would impact upon reward-dependent 
learning. The non-mnemonic interpretation is supported by a failure of CBD to prevent the 
acquisition of amphetamine place preference (Parker et al., 2004). However, while it appears 
that CBD does not disrupt the formation of amphetamine-related memories, this does not rule 
out potential effects on memories formed in relation to other drugs of abuse. 
 Subsequent to their acquisition, CBD might affect the expression of drug memories. 
Here there appears to be a contrast depending upon the drug reward under study. Acute 
administration of CBD (5 and 10 mg kg
-1
) did not alter cocaine self-administration or cue-
induced relapse to cocaine seeking (Mahmud et al., 2016), and so failed to replicate an earlier 
study of heroin self-administration (Ren et al., 2009). While CBD (5 and 20 mg kg
-1
) 
similarly did not alter heroin self-administration, there were effects on cue-induced relapse to 
heroin seeking (Ren et al., 2009), a measure of cue-heroin memory expression. CBD (5 mg 
kg
-1
) reduced responding at a cue-induced relapse test, but only when given 24 hr, and not 30 
min, prior to the test. This long-lasting impact upon the expression of the cue-heroin memory 
was even more persistent (up to 14 days) when three consecutive daily injections of 5 mg kg
-1
 
CBD were given. This ability of CBD to have such long-lasting effects may be mediated by 
an upregulation of AMPA GluR1 receptors in the nucleus accumbens (Ren et al., 2009).  
 The impaired expression of cue-heroin relapse in response to CBD administration in 
animals suggests that this drug might have anti-relapse properties in opiate addiction in 
humans. This has been explored in a preliminary study of heroin addicts, in which 
participants were given daily doses of CBD (400 or 800 mg) or placebo for 3 days (Hurd et 
al., 2015). CBD reduced craving both 24 hr and 7 days later, mirroring the preclinical rodent 
study (Ren et al., 2009). This beneficial effect of CBD may not be limited to opiate addiction 
as a conceptually similar, albeit more modest, effect was also previously observed in tobacco 
smokers (Morgan et al., 2013). In this small week-long study, smokers were instructed to 
inhale a metered dose of CBD (400 µg) or placebo when they felt like smoking. CBD acutely 
reduced the number of cigarettes smoked but this effect was not maintained after the 
cessation of CBD administration. Interestingly, and in contrast to the heroin study, CBD did 
not alter craving, either acutely or persistently. Therefore, it is not clear whether CBD has 
generalised effects on the expression of cue-drug memory to elicit craving and precipitate 
relapse, or whether its effects are specific to certain classes of addictive drugs. 
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 For the maintenance (i.e. reconsolidation) of drug-related memories, there is a single 
study on morphine and cocaine conditioned place preference. When the place preference 
memory was briefly reactivated in order to trigger reconsolidation, CBD administration (10 
mg kg
-1
) immediately thereafter led to an impairment in the subsequent maintenance of both 
cocaine and morphine memories to reduce place preference at test (de Carvalho and 
Takahashi, 2016). This was a long-lasting effect, which is usually evidence for 
reconsolidation impairments. However, the study lacked a true non-reactivation control, and 
so the long-lasting impairment, especially for morphine place preference, is not dissimilar to 
the aforementioned persistent reduction in the expression of cue-heroin memories in the self-
administration setting (Ren et al., 2009). Therefore, it remains unclear whether CBD indeed 
impairs the reconsolidation of drug memories. Nevertheless, there are indications from the 
comparison between the place preference and self-administration studies to suggest that their 
results might be underpinned by qualitatively different processes. For example, while the 
CBD-induced impairment failed to ameliorate heroin-primed reinstatement of drug seeking 
(Ren et al., 2009), post-reactivation CBD did prevent morphine-primed reinstatement of place 
preference (de Carvalho and Takahashi, 2016). Moreover, the contrasting effects of post-
reactivation CBD and acute CBD treatment on the subsequent expression of cocaine 
memories (de Carvalho and Takahashi, 2016) suggests that the impairment in cocaine place 
preference is not simply explained by long-lasting modulation of drug memory expression. 
 Similarly, there is a single study of CBD and drug memory extinction. Injection of 
CBD (5 mg kg
-1
) prior to an extinction trial enhanced the subsequent reduction in cocaine and 
amphetamine place preference (Parker et al., 2004). Despite the lack of a no-extinction 
control, the observation that CBD reduces the expression of stimulant-induced place 
preference again suggests that such a reduction was, at least in part, due to the concomitant 
extinction trial. Interestingly, the effect of CBD to reduce cocaine and amphetamine place 
preference in this extinction study (Parker et al., 2004) is rather similar to the previous 
observation that CBD impairs the reconsolidation of morphine and cocaine memories in the 
same place preference setting (de Carvalho and Takahashi, 2016). Indeed, while there was a 
difference in the timing of CBD administration between the two studies, the single 
behavioural trial that served to extinguish (Parker et al., 2004) or destabilise (de Carvalho and 
Takahashi, 2016) the drug memory did not differ greatly. The extinction trial was 15 min in 
duration, compared to a 10 min reactivation trial, although the former was a confinement to 
the drug-paired chamber, whereas the latter was a test. Moreover, the conditioning 
parameters were rather similar across the two studies, and also in prior studies of 
 This article is protected by copyright. All rights reserved. 
reconsolidation that have used 30-min confined reactivation trials for amphetamine place 
preference (Sakurai et al., 2007), 20-min confined reactivation trials for cocaine place 
preference (Valjent et al., 2006) and 10-min confined reactivation trials for morphine and 
nicotine place preference (Wang et al., 2008; Fang et al., 2011). Given also that the 
parameters of appetitive memory reconsolidation and extinction are usually well 
distinguished, such that they are each typically defined by much different durations of context 
re-exposure or numbers of cue presentations (Flavell and Lee, 2013), it is unclear if CBD 
both enhances extinction and impairs reconsolidation of drug memories. It is perhaps more 
likely that the two observed effects of CBD to reduce later drug place preference (Parker et 
al., 2004; de Carvalho and Takahashi, 2016) instead reflect qualitatively similar processes. 
Appealing simply to the parametric comparisons presented above, we would conclude that 
there is stronger evidence for CBD impairing drug memory reconsolidation than there is for it 
enhancing drug memory extinction. Furthermore, given that pharmacological enhancement of 
extinction is usually dependent upon appreciable extinction-mediated memory reduction 
(Webber et al., 2007; Bouton et al., 2008), and there was no evidence for any such reduction 
in the CBD study (Parker et al., 2004), it remains unclear if CBD actually enhances drug 
memory extinction. 
 
Concluding remarks and future directions 
Converging lines of evidence have established that acute CBD treatment is anxiolytic 
in both animals and humans. A growing number of preclinical studies also indicate that this 
drug reduces fear memory expression when given acutely. Importantly, CBD results in an 
enduring reduction in learned fear expression when given in conjunction with fear memory 
reconsolidation or extinction by disrupting the former and facilitating the latter. This makes 
CBD a potential candidate for testing as a pharmacological adjunct to psychological therapies 
or behavioural interventions used in treating PTSD and phobias. These effects of CBD are 
mediated at least in part by 5-HT1A receptors and indirectly via endocannabinoid-mediated 
action on cannabinoid receptors, although the involvement of other possible pharmacological 
mechanisms has not yet been investigated. Studies have begun to elucidate the neural circuit 
mechanisms underlying the effects of CBD on anxiety and learned fear. The recent functional 
imaging studies in humans that have examined the alterations in brain activity that 
accompany the anxiolytic effects of CBD may inform future preclinical and clinical studies 
investigating the wider neural circuitry involved in mediating its effects on learned fear. In 
contrast to anxiety and learned fear, research on CBD regulation of addictive drug memory 
 This article is protected by copyright. All rights reserved. 
processing is still in its infancy. Further studies are therefore needed to determine the 
psychological, pharmacological and brain mechanisms involved in the attenuation of drug 
memory expression by CBD in relation to different classes of abused drugs. Given the 
significant co-morbidity between anxiety-related and substance abuse disorders, CBD could 
also be investigated as a common treatment for such disorders. An outstanding issue is to 
determine the effects of chronic CBD treatment on different emotional memory processes. 
For example, one potential therapeutic strategy is to use CBD chronically to reduce 
symptoms by dampening fear and/or drug memory expression. However, CBD given acutely 
during the psychological therapy session to impair memory reconsolidation or enhance 
extinction might be sufficient for facilitating such treatment. Another important consideration 
is how CBD would be delivered in the treatment of these disorders. Most of the recreationally 
used cannabis available today contains low levels of CBD and high levels of THC, which can 
exacerbate symptoms, although cannabis strains containing a more favourable CBD:THC 
ratio might be an option (Hurd et al., 2015). Similarly, novel formulations of CBD containing 
only trace amounts of other phytocannabinoids have recently become available for the 
putative treatment of childhood epileptic disorders (e.g. Epidiolex, GW Pharmaceuticals; 
Gofshteyn et al., 2016). In summary, this line of research may lead to the potential 
development of CBD for use in treating anxiety-related and substance abuse disorders in the 
future.  
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Fig 1. The main molecular targets and potential mechanisms of action of CBD. This drug 
inhibits both fatty acid amide hydrolase (FAAH), the enzyme which metabolizes 
anandamide, and fatty acid-binding proteins (FAPBs), which mediate the transport of 
anandamide to FAAH; both mechanisms ultimately result in the indirect activation of 
cannabinoid type 1 (CB1) and/or type 2 (CB2) receptors. CBD also activates the serotonin1A 
(5-HT1A) receptor, peroxisome proliferator-activated receptor gamma (PPARγ), and the 
transient receptor potential (TRP) channels TRPV1, TRPA1, and TRPV2. Finally, CBD 
inhibits adenosine reuptake and antagonizes GPR55, TRPM8 and T-type Ca
2+
 channels. 5-
HT1A and (indirect) cannabinoid receptor activation are the mechanisms that have been 
implicated in the anxiolytic effects of CBD to date (see Ibeas Bih et al. (2015) and 
McPartland et al. (2015) for further details). 
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Table 1. CBD effects on anxiety-like behaviour in male animals. 5-HT1A: serotonin1A; BNST: bed nucleus of the stria terminalis; BZD: 
benzodiazepine; CB1: cannabinoid type 1; CUS: chronic unpredictable stress, dlPAG: dorsolateral periaqueductal grey; EPM: elevated plus-
maze, ETM: elevated T-maze; ICR: Institute of Cancer Research; i.c.v.: intracerebroventricular; IL: infralimbic, i.p.: intraperitoneal; LDT: light-
dark test, MBT: marble burying test, NSF: novelty suppressed feeding, PL: prelimbic; SHR: spontaneously hypertensive rats; THC: delta-9-
tetrahydrocannabinol; TRPV1: transient receptor potential vanilloid 1. 
 
Reference Test used Strain, species, effective dose, and 
route/site of administration 
Effect Pharmacological 
mechanism 
Guimarães et 
al., 1990 
EPM Wistar rats, 2.5-10 mg kg
-1
, i.p. Anxiolytic (bell-shaped dose-
response curve) 
Not tested 
Onaivi et al., 
1990 
EPM ICR mice, 1 and 10 mg kg
-1
, i.p.  Anxiolytic (bell-shaped dose-
response curve) 
BZD (blocked by flumazenil)  
Guimarães et 
al., 1994 
EPM Wistar rats, 5 mg kg
-1
, i.p. Anxiolytic Not tested 
Bitencourt et 
al., 2008 
Fear-potentiated EPM Wistar rats, 6.4 nmol, i.c.v. Anxiolytic Not tested 
Campos and 
Guimarães, 
2008 
EPM Wistar rats, 30 nmol, intra-dlPAG Anxiolytic (bell-shaped dose-
response curve) 
5-HT1A receptor activation 
Campos and 
Guimarães, 
2009 
EPM Wistar rats, 30 nmol, intra-dlPAG 
(60 nmol effective when combined 
with a TRPV1 channel antagonist) 
Anxiolytic Lack of anxiolytic effect of 
high doses associated with 
TRPV1 channel activation 
Malone et al., 
2009 
THC-induced decrease in 
social interaction 
Sprague Dawley rats, 20 mg kg
-1
, 
i.p. 
Anxiolytic Not tested 
Resstel et al., 
2009 
Restraint stress, autonomic 
changes, delayed (24 h) 
anxiogenic effect in EPM 
Wistar rats, 10 mg kg
-1
, i.p. Anti-stress 5-HT1A receptor activation 
Casarotto et 
al., 2010 
MBT C57BL/6 mice, 15-60 mg kg
-1
, i.p. Anti-compulsive Indirect CB1 receptor 
activation 
Soares et al., 
2010 
ETM, electrical 
stimulation of dlPAG 
Wistar rats, 15-60 nmol, intra- 
dlPAG 
Anxiolytic/panicolytic 5-HT1A receptor activation 
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Long et al., 
2010 
Open field and light-dark 
tests 
C57BL/6 mice, 1 mg kg
-1
 (light-
dark test) and 50 mg kg
-1
 (open-
field), i.p., daily for 21 days 
Anxiolytic Not tested 
Gomes et al., 
2011 
EPM Wistar rats, 30 nmol, intra-BNST Anxiolytic 5-HT1A receptor activation 
Granjeiro et 
al., 2011 
Restraint stress, autonomic 
reactivity, delayed (24 h) 
anxiogenic effect in EPM 
Wistar rats, 30 nmol, intra-cisterna 
magna 
Anti-stress Not tested 
Campos et al., 
2012 
EPM after predator (cat) 
exposure 
Wistar rats, 5 mg kg
-1
, i.p., daily for 
7 days 
Anxiolytic 5-HT1A receptor activation 
Deiana et al., 
2012 
MBT Swiss mice, 120 mg kg
-1
, orally or 
i.p. 
Anticompulsive Not tested 
Long et al., 
2012 
Open field and light-dark 
tests 
C57BL/6 Arc mice, 1 and 100 mg 
kg
-1
, i.p. daily for 13 days 
Anxiolytic  
(open-field only) 
Not tested 
Uribe-Mariño 
et al., 2012 
Snake exposure Swiss mice, 0.3-30 mg kg
-1
, i.p. Panicolytic Not tested 
Hsiao et al., 
2012 
Repeated EPM and open-
field  
Wistar rats, 3.2 nmol, intra-central 
amygdaloid nucleus 
Anxiolytic Not tested 
Campos et al., 
2013 
EPM and NSF C57BL/6 mice, 30 mg kg
-1
, daily 
for 14 days (CUS-exposed animals) 
Anti-stress CB1 receptor-mediated 
facilitation of hippocampal 
neurogenesis 
O‟Brien et al., 
2013 
Light-dark test Sprague Dawley rats, 2.5 mg kg
-1
, 
i.p. for 14 days 
No effect Not tested 
Twardowschy 
et al., 2013 
Snake exposure Swiss mice, 3.0 mg kg
-1
, i.p. Panicolytic 5-HT1A receptor activation 
Almeida et 
al., 2013 
Social interaction test Wistar and SHR rats, 1 mg kg
-1
, i.p. Increased social interaction 
(Wistar rats only) 
Not tested 
Cheng et al., 
2014 
EPM C57BL/6J mice, 20 mg kg
-1
, i.p. 
daily for 21 days 
No effect Not tested 
Fogaça et al., 
2014 
EPM Wistar rats, 30 nmol, intra-PL 
cortex 
Anxiogenic (bell-shaped dose 
response curve), anxiolytic 24 hr 
after restraint stress 
5-HT1A receptor activation 
 This article is protected by copyright. All rights reserved. 
Nardo et al., 
2014 
MBT Swiss mice, 30 mg kg
-1
, i.p. Attenuated mCPP-induced 
increase in marble-burying (bell-
shaped dose response curve) 
Indirect CB1 receptor 
activation 
Marinho et 
al., 2015 
EPM Wistar rats, 15-30 nmol, intra-IL 
cortex 
Anxiolytic (bell-shaped dose 
response curve), no effect 24 hr 
after restraint stress 
5-HT1A receptor activation 
Todd and 
Arnold, 2016 
Open-field C57BL/6 mice, 10 mg kg
-1
, i.p. Prevented THC- induced 
anxiogenesis 
Not tested 
Schiavon et 
al., 2016 
EPM Swiss mice, 3 mg kg
-1
, i.p. Anxiolytic Not tested 
 
  
 This article is protected by copyright. All rights reserved. 
Table 2. CBD effects on learned fear processing in male animals. 5-HT1A: serotonin1A; AFC: auditory fear conditioning; BNST: bed nucleus of 
the stria terminalis; BZD: benzodiazepine; CB1: cannabinoid type 1; CB2: cannabinoid type 2; CFC: contextual fear conditioning; i.c.v.: 
intracerebroventricular; IL: infralimbic; i.p.: intraperitoneal; OFC: olfactory fear conditioning; PL: prelimbic; THC: delta-9-
tetrahydrocannabinol. 
Reference Test used Strain, species, effective dose and 
route/site of administration 
Effect Pharmacological 
mechanism 
Studies conducted in operant conditioning paradigms 
Silveira Filho 
and Tufik, 1981 
Geller-Seifter 
conflict test  
Wistar rats, 100 mg kg
-1
, i.p. No effect Not tested 
Musty et al., 
1985 
Vogel punished 
licking test  
Sprague-Dawley rats, 5-10 mg kg
-1
, 
i.p. 
Anxiolytic (bell-shaped dose-response 
curve) 
Not tested 
Moreira et al., 
2006 
Vogel punished 
licking test 
Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic Not blocked by BZD 
antagonism (flumazenil)  
Gomes et al., 
2011 
Vogel punished 
licking test 
Wistar rats, 30-60 nmol, intra-BNST Anxiolytic 5-HT1A receptor activation 
Studies conducted in classical (Pavlovian) conditioning paradigms 
Zuardi and 
Karniol, 1983 
AFC  Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Resstel et al., 
2006 
CFC Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Bitencourt et al., 
2008 
CFC Wistar rats, 6.4 nmol, i.c.v. Facilitated fear memory extinction Indirect CB1 receptor 
activation 
Lemos et al., 
2010  
CFC Wistar rats, 10 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) Not tested 
Lemos et al., 
2010 
CFC Wistar rats, 30 nmol, intra-PL cortex Anxiolytic (decreased fear expression) Not tested 
Lemos et al., 
2010 
CFC Wistar rats, 30 nmol, intra-IL cortex Anxiogenic (increased fear expression) Not tested 
ElBatsh et al., 
2012 
CFC Lister-hooded rats, 10 mg kg
-1
, i.p. 
daily for 14 days 
Anxiogenic (increased fear expression) Decreased hippocampal 
BDNF and TrkB, reduced 
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frontal cortex phospho-
ERK1/2 expression 
Gomes et al., 
2012 
CFC Wistar rats, 30-60 nmol, intra-BNST Anxiolytic (decreased fear expression) 5-HT1A receptor activation 
Levin et al., 
2012 
CFC Wistar and SHR rats, 1-15 mg kg
-1
, 
i.p. 
Anxiolytic (decreased fear expression) 
and/or disrupted fear memory formation 
(Wistar rats only) 
Not tested 
Stern et al., 2012 CFC Wistar rats, 3-30 mg kg
-1
, i.p. Disrupted fear memory reconsolidation 
(bell-shaped dose response curve) 
Indirect CB1 receptor 
activation 
Do Monte et al., 
2013 
CFC Long–Evans hooded rats, 1.3 nmol, 
intra-IL cortex 
Facilitated fear memory extinction Indirect CB1 receptor 
activation 
Cheng et al., 
2014 
AFC C57BL/6J mice, 20 mg kg
-1
, i.p. daily 
for 21 days 
No effect Not tested 
Fogaca et al., 
2014 
CFC Wistar rats, 30 nmol, intra-PL cortex Anxiolytic (decreased fear expression) 5-HT1A receptor activation 
Gazarini et al., 
2014 
CFC Wistar rats, 10 mg kg
-1
, i.p. Disrupted fear memory reconsolidation Not tested 
Stern et al., 2014 CFC Wistar rats, 10 mg kg
-1
, i.p. Disrupted fear memory reconsolidation  Indirect CB1 receptor 
activation in PL cortex 
Marinho et al., 
2015 
CFC Wistar rats, 30 nmol, intra-IL cortex Anxiogenic (increased fear expression) 5-HT1A receptor activation 
Stern et al., 2015 CFC Wistar rats, 1 mg kg
-1
 + THC 0.1 mg 
kg
-1
, i.p. 
Disrupted fear memory reconsolidation Not tested 
Norris et al., 
2016 
OFC Sprague Dawley rats, 0.03-0.32 nmol, 
intra-nucleus accumbens shell 
Disrupted fear memory formation 
(acquisition) 
5-HT1A receptor activation 
Song et al., 2016 CFC Lister hooded rats, 10 mg kg
-1
, i.p., 
before extinction (after weak or strong 
conditioning) 
Impaired or enhanced extinction after 
weak or strong conditioning, 
respectively 
Not tested 
Jurkus et al., 
2016 
AFC Lister hooded rats, 5-20 mg kg
-1
, i.p. Anxiolytic (decreased fear expression) 
at highest dose, no effect on extinction 
Not tested 
Stern et al., 2016 CFC Wistar rats, 10-30 mg kg
-1
, i.p. Disrupted fear memory consolidation Indirect CB1 or CB2 
receptor activation 
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Table 3. CBD effects on anxiety in humans. 5-HT1A: serotonin1A; fMRI: functional magnetic resonance imaging; PTSD: post-traumatic stress 
disorder; SCR: skin conductance response; SPECT: single-photon emission computed tomography; THC: delta-9-tetrahydrocannabinol. 
Reference  Subjects and test(s) used  Effective dose and route 
of administration 
Effect Possible pharmacological or neural 
mechanism 
Zuardi et al., 
1982 
Healthy subjects, THC-
induced anxiety 
~70 mg (1 mg kg
-1
) 
orally 
Prevented the anxiogenic 
effects of THC  
Not tested 
Zuardi et al., 
1993 
Healthy subjects, 
simulated public speaking-
induced anxiety 
300 mg orally Prevented public speaking-
induced increase in 
anxiety 
Not tested (effects similar to the 5-HT1A 
receptor partial agonist ipsapirone) 
Crippa et al., 
2004 
Healthy subjects, SPECT 400 mg orally Anxiolytic Decreased blood flow in medial temporal 
structures and posterior cingulate gyrus 
Fusar-Poli et 
al., 2009,  2010 
Healthy subjects, fearful 
faces, fMRI 
600 mg orally Anxiolytic (trend) Decreased blood flow in amygdala and 
anterior cingulate cortex that correlated 
with a reduced SCR to fearful faces 
Bergamaschi et 
al., 2011 
Social anxiety disorder 
patients, simulated public 
speaking-induced anxiety 
600 mg orally Anxiolytic Not tested 
Crippa et al., 
2011 
Generalized anxiety 
disorders patients, SPECT 
400 mg orally Decreased subjective 
anxiety 
Altered blood flow in limbic and 
paralimbic brain areas 
Hurd et al., 
2015 
Abstinent heroin abusers, 
heroin cue-induced anxiety 
400 or 800 mg orally Decreased subjective 
anxiety (preliminary data) 
Not tested 
Shannon and 
Opila-Lehman, 
2016 
A 10 year-old girl with 
PTSD (case report) 
At least 25 mg daily for 5 
months 
Reduced anxiety and 
improved sleep  
Not tested 
 
